Technical Analysis for BOLT - Bolt Biotherapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 0.76 | -0.32% | 0.00 |
BOLT closed down 0.32 percent on Friday, May 31, 2024, on 22 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| NR7-2 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | -0.32% |
| Alert | Time |
|---|---|
| Possible NR7 | 1 day ago |
| Possible Inside Day | 1 day ago |
| 60 Minute Opening Range Breakdown | 1 day ago |
| Up 1% | 1 day ago |
| Possible NR7 | 3 days ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors. Its preclinical stage product candidates include carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade; and myeloid modulators. Bolt Biotherapeutics, Inc. was founded in 2015 and is based Redwood city, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Medicine Pharmaceutical Products Tumor Cancer Immunotherapy Breast Cancer Immune Checkpoint Her2/Neu
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Medicine Pharmaceutical Products Tumor Cancer Immunotherapy Breast Cancer Immune Checkpoint Her2/Neu
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 1.81 |
| 52 Week Low | 0.7341 |
| Average Volume | 248,644 |
| 200-Day Moving Average | 1.08 |
| 50-Day Moving Average | 1.10 |
| 20-Day Moving Average | 0.94 |
| 10-Day Moving Average | 0.77 |
| Average True Range | 0.07 |
| RSI (14) | 30.07 |
| ADX | 31.06 |
| +DI | 14.81 |
| -DI | 33.54 |
| Chandelier Exit (Long, 3 ATRs) | 1.14 |
| Chandelier Exit (Short, 3 ATRs) | 0.93 |
| Upper Bollinger Bands | 1.35 |
| Lower Bollinger Band | 0.53 |
| Percent B (%b) | 0.28 |
| BandWidth | 87.15 |
| MACD Line | -0.11 |
| MACD Signal Line | -0.10 |
| MACD Histogram | -0.0128 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.78 | ||||
| Resistance 3 (R3) | 0.78 | 0.77 | 0.77 | ||
| Resistance 2 (R2) | 0.77 | 0.77 | 0.77 | 0.77 | |
| Resistance 1 (R1) | 0.77 | 0.77 | 0.76 | 0.76 | 0.77 |
| Pivot Point | 0.76 | 0.76 | 0.76 | 0.76 | 0.76 |
| Support 1 (S1) | 0.75 | 0.76 | 0.75 | 0.75 | 0.74 |
| Support 2 (S2) | 0.75 | 0.75 | 0.75 | 0.74 | |
| Support 3 (S3) | 0.74 | 0.75 | 0.74 | ||
| Support 4 (S4) | 0.74 |
